Eli Lilly 2008 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2008 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

FINANCIALS
19
Zyprexa sales in the U.S. increased 6 percent in
2007, driven by higher net selling prices, partially offset
by lower demand. Sales outside the U.S. increased
12 percent, driven by the favorable impact of foreign
exchange rates and increased demand.
Sales of Cymbalta increased 58 percent in the U.S.,
driven primarily by strong demand. Sales outside the
U.S. increased 70 percent, driven by increased demand
and the favorable impact of foreign exchange rates.
Sales of Gemzar increased 10 percent in the U.S.,
driven by higher prices and increased demand. Sales
outside the U.S. increased 16 percent, driven by
increased demand and the favorable impact of foreign
exchange rates.
Sales of Humalog increased 9 percent in the
U.S., driven by higher prices and increased demand.
Sales outside the U.S. increased 20 percent, driven by
increased demand and the favorable impact of foreign
exchange rates, partially offset by declining prices.
Total worldwide sales of Cialis were $1.22 billion
and $971.0 million during 2007 and 2006, respectively.
This includes $72.7 million of sales in the Lilly ICOS
joint-venture territories for the 2007 period prior to the
acquisition of ICOS. Worldwide sales grew 25 percent in
2007. U.S. sales increased 20 percent in 2007, driven by
increased demand and higher prices. Sales outside the
U.S. increased 28 percent in 2007, driven by increased
demand, the favorable impact of foreign exchange
rates, and higher prices.
Sales of Evista increased 6 percent in the U.S., driv-
en by higher prices. Sales outside the U.S. increased
1 percent, driven by the favorable impact of foreign
exchange rates, partially offset by lower prices and
lower demand.
Sales of Humulin decreased 1 percent in the U.S.,
driven by lower demand, partially offset by higher
prices. Sales outside the U.S. increased 11 percent,
driven by increased demand and the favorable impact of
foreign exchange rates, partially offset by lower prices.
Sales of Alimta increased 28 percent in the U.S.,
driven by increased demand and, to a lesser extent,
higher prices. Sales outside the U.S. increased 55
percent, driven by increased demand and, to a lesser
extent, the favorable impact of foreign exchange rates.
Sales of Forteo increased 19 percent in the U.S.,
driven by higher net selling prices. U.S. sales growth
benefi ted from access to medical coverage through
the Medicare Part D program and decreased utiliza-
tion of our U.S. patient assistance program and, to a
lesser extent, increased demand. Sales outside the U.S.
increased 21 percent, driven by increased demand and
the favorable impact of foreign exchange rates.
Sales of Strattera decreased 9 percent in the U.S.,
as a result of decreased demand. Sales outside the U.S.
The following table summarizes our net sales activity in 2007 compared with 2006:
Year Ended Year Ended Percent
December 31, 2007 December 31, 2006 Change
Product U.S.1 Outside U.S. Total Total from 2006
(Dollars in millions)
Zyprexa . . . . . . . . . . . . . . . . . . . . . . $ 2,236.0 $2,525.0 $ 4,761.0 $ 4,363.6 9
Cymbalta. . . . . . . . . . . . . . . . . . . . . 1,835.6 267.3 2,102.9 1,316.4 60
Gemzar . . . . . . . . . . . . . . . . . . . . . . 670.0 922.4 1,592.4 1,408.1 13
Humalog . . . . . . . . . . . . . . . . . . . . . 888.0 586.6 1,474.6 1,299.5 13
Cialis2 . . . . . . . . . . . . . . . . . . . . . . . 423.8 720.0 1,143.8 215.8 NM
Evista . . . . . . . . . . . . . . . . . . . . . . . . 706.1 384.6 1,090.7 1,045.3 4
Animal health products. . . . . . . . . 480.9 514.9 995.8 875.5 14
Humulin. . . . . . . . . . . . . . . . . . . . . . 365.2 620.0 985.2 925.3 6
Alimta . . . . . . . . . . . . . . . . . . . . . . . 448.0 406.0 854.0 611.8 40
Forteo . . . . . . . . . . . . . . . . . . . . . . . 494.1 215.2 709.3 594.3 19
Strattera . . . . . . . . . . . . . . . . . . . . . 464.6 104.8 569.4 579.0 (2)
Humatrope® . . . . . . . . . . . . . . . . . . 213.6 227.2 440.8 415.6 6
Actos® . . . . . . . . . . . . . . . . . . . . . . . 150.8 219.8 370.6 448.5 (17)
Byetta . . . . . . . . . . . . . . . . . . . . . . . 316.5 14.2 330.7 219.0 51
Other pharmaceutical products . . 452.3 760.0 1,212.3 1,373.3 (12)
Total net sales . . . . . . . . . . . . . . $10,145.5 $8,488.0 $18,633.5 $15,691.0 19
NM—Not meaningful
1U.S. sales include sales in Puerto Rico.
2Prior to the acquisition of ICOS, the Cialis sales shown in the table above represent results only in the territories in which we marketed
Cialis exclusively. The remaining sales relate to the joint-venture territories of Lilly ICOS LLC (North America, excluding Puerto Rico,
and Europe). Our share of the joint-venture territory sales, net of expenses and income taxes, is reported in other—net in our consoli-
dated statements of operations. Subsequent to the acquisition, all Cialis product sales are reported in our net sales.